cefuroxime has been researched along with Escherichia coli Infections in 40 studies
Cefuroxime: Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, GONORRHEA, and HAEMOPHILUS.
cefuroxime : A 3-(carbamoyloxymethyl)cephalosporin compound having a 7-(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido side chain.
Escherichia coli Infections: Infections with bacteria of the species ESCHERICHIA COLI.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The objectives of this study were to assess the clinical efficacy of intravenous cefuroxime as an empirical antibiotic for the treatment of hospitalized women with acute pyelonephritis (APN) caused by Escherichia coli." | 7.83 | Use of cefuroxime for women with community-onset acute pyelonephritis caused by cefuroxime-susceptible or -resistant Escherichia coli. ( Chang, UI; Kim, HW; Wie, SH, 2016) |
| "To present the outcomes of prophylaxis of postoperative endophthalmitis following cataract surgery with intracameral Cefuroxime." | 7.75 | [Prophylaxis of postoperative endophthalmitis with intracameral cefuroxime: a five years' experience]. ( Arteta, M; De la Rosa, G; Díez, MR; Girón, C; Pascual, R, 2009) |
| "The following results were obtained from the fundamental and clinical studies of cefuroxime, a new synthetic cephalosporin, in pediatric patients with purulent meningitis." | 7.66 | [Fundamental and clinical studies of cefuroxime in pediatric purulent meningitis (author's transl)]. ( Hori, M; Kumagai, K; Kurosu, Y; Toyonaga, Y, 1980) |
| "Cefuroxime axetil is an effective antimicrobial for uncomplicated pediatric UTIs." | 6.67 | Two-day therapy with cefuroxime axetil is effective for urinary tract infections in children. ( Collins, JJ; Feld, LG; Kornberg, AE; Mydlow, PK; Sherin, K; Veiga, P, 1994) |
| " The objectives of this study were to assess the clinical efficacy of intravenous cefuroxime as an empirical antibiotic for the treatment of hospitalized women with acute pyelonephritis (APN) caused by Escherichia coli." | 3.83 | Use of cefuroxime for women with community-onset acute pyelonephritis caused by cefuroxime-susceptible or -resistant Escherichia coli. ( Chang, UI; Kim, HW; Wie, SH, 2016) |
| "Nitrofurantoin has been used for decades for the treatment of urinary tract infections (UTIs), but clinically significant resistance in Escherichia coli is uncommon." | 3.80 | An in vitro deletion in ribE encoding lumazine synthase contributes to nitrofurantoin resistance in Escherichia coli. ( Adriaenssens, N; Coenen, S; Godycki-Cwirko, M; Goossens, H; Harbarth, S; Kowalczyk, A; Lammens, C; Malhotra-Kumar, S; Stewardson, A; Vervoort, J; Xavier, BB, 2014) |
| "To present the outcomes of prophylaxis of postoperative endophthalmitis following cataract surgery with intracameral Cefuroxime." | 3.75 | [Prophylaxis of postoperative endophthalmitis with intracameral cefuroxime: a five years' experience]. ( Arteta, M; De la Rosa, G; Díez, MR; Girón, C; Pascual, R, 2009) |
| "The following results were obtained from the fundamental and clinical studies of cefuroxime, a new synthetic cephalosporin, in pediatric patients with purulent meningitis." | 3.66 | [Fundamental and clinical studies of cefuroxime in pediatric purulent meningitis (author's transl)]. ( Hori, M; Kumagai, K; Kurosu, Y; Toyonaga, Y, 1980) |
| "Cefuroxime axetil is an effective antimicrobial for uncomplicated pediatric UTIs." | 2.67 | Two-day therapy with cefuroxime axetil is effective for urinary tract infections in children. ( Collins, JJ; Feld, LG; Kornberg, AE; Mydlow, PK; Sherin, K; Veiga, P, 1994) |
| "Renal parenchymal malacoplakia is a rare cause of acute renal failure." | 2.42 | Renal parenchymal malacoplakia: a rare cause of ARF with a review of recent literature. ( Chan, KW; Kung, WH; Li, R; Tam, VK, 2003) |
| "Cefuroxime was chosen as the PBP-3-active antibiotic and tobramycin represented the aminoglycosides." | 1.56 | Mode of bacterial killing affects the inflammatory response and associated organ dysfunctions in a porcine E. coli intensive care sepsis model. ( Larsson, A; Lipcsey, M; Maudsdotter, L; Sjölin, J; Skorup, P, 2020) |
| "Emphysematous cystitis is a rare disease with a high mortality rate." | 1.43 | [Emphysematous cystitis]. ( Haferkamp, A; Hüsch, T; Müller, T; Rheinboldt, V; Thalhammer, A, 2016) |
| "All animals developed severe sepsis/septic shock." | 1.40 | Beneficial antimicrobial effect of the addition of an aminoglycoside to a β-lactam antibiotic in an E. coli porcine intensive care severe sepsis model. ( Castegren, M; Jonsson, AB; Larsson, A; Lipcsey, M; Maudsdotter, L; Sjölin, J; Skorup, P, 2014) |
| " The population was characterized by a population pharmacokinetic model, and distributions of CLcr and body weight were reflective of the target group." | 1.35 | Estimation of cefuroxime dosage using pharmacodynamic targets, MIC distributions, and minimization of a risk function. ( Cars, O; Jönsson, S; Karlsson, MO; Viberg, A, 2008) |
| " Using pharmacokinetic parameters of the plasma concentrations in vivo and those of the Hill equation the corresponding time course of ER was calculated and by integration with respect to time (0tERdt), an estimate was obtained of the effect on bacteria." | 1.28 | Antibacterial activity of four cephalosporins in an experimental infection in relation to in vitro effect and pharmacokinetics. ( Brus-Weijer, L; Krul, AM; Mattie, H; van Dokkum, AM; van Strijen, E, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (15.00) | 18.7374 |
| 1990's | 7 (17.50) | 18.2507 |
| 2000's | 13 (32.50) | 29.6817 |
| 2010's | 11 (27.50) | 24.3611 |
| 2020's | 3 (7.50) | 2.80 |
| Authors | Studies |
|---|---|
| Thønnings, S | 1 |
| Jensen, KS | 1 |
| Nielsen, NB | 1 |
| Skjønnemand, M | 1 |
| Hansen, DS | 1 |
| Lange, KHW | 1 |
| Frimodt-Møller, N | 2 |
| Demirci-Duarte, S | 1 |
| Unalan-Altintop, T | 1 |
| Eser, OK | 1 |
| Cakar, A | 1 |
| Altun, B | 1 |
| Sancak, B | 1 |
| Gur, D | 1 |
| Skorup, P | 3 |
| Maudsdotter, L | 3 |
| Lipcsey, M | 3 |
| Larsson, A | 3 |
| Sjölin, J | 3 |
| Bosch-Nicolau, P | 1 |
| Falcó, V | 1 |
| Viñado, B | 1 |
| Andreu, A | 1 |
| Len, O | 1 |
| Almirante, B | 1 |
| Pigrau, C | 1 |
| Tano, E | 1 |
| Castegren, M | 2 |
| Kõljalg, S | 1 |
| Truusalu, K | 1 |
| Stsepetova, J | 1 |
| Pai, K | 1 |
| Vainumäe, I | 1 |
| Sepp, E | 1 |
| Mikelsaar, M | 1 |
| Jonsson, AB | 1 |
| Vervoort, J | 1 |
| Xavier, BB | 1 |
| Stewardson, A | 1 |
| Coenen, S | 1 |
| Godycki-Cwirko, M | 1 |
| Adriaenssens, N | 1 |
| Kowalczyk, A | 1 |
| Lammens, C | 1 |
| Harbarth, S | 1 |
| Goossens, H | 1 |
| Malhotra-Kumar, S | 1 |
| Can, F | 1 |
| Azap, OK | 1 |
| Seref, C | 1 |
| Ispir, P | 1 |
| Arslan, H | 1 |
| Ergonul, O | 1 |
| Süzük, S | 1 |
| Kaşkatepe, B | 1 |
| Avcıküçük, H | 1 |
| Aksaray, S | 1 |
| Başustaoğlu, A | 1 |
| Chang, UI | 1 |
| Kim, HW | 1 |
| Wie, SH | 1 |
| Hüsch, T | 1 |
| Rheinboldt, V | 1 |
| Thalhammer, A | 1 |
| Müller, T | 1 |
| Haferkamp, A | 1 |
| Ilhan, G | 1 |
| Verit Atmaca, FF | 1 |
| Kaya, A | 1 |
| Ergin, AH | 1 |
| Gökmen Karasu, AF | 1 |
| Turfan, M | 1 |
| Taskinen, S | 1 |
| Giordano, S | 1 |
| Rintala, R | 1 |
| Viberg, A | 1 |
| Cars, O | 1 |
| Karlsson, MO | 1 |
| Jönsson, S | 1 |
| Díez, MR | 1 |
| De la Rosa, G | 1 |
| Pascual, R | 1 |
| Girón, C | 1 |
| Arteta, M | 1 |
| Källman, O | 1 |
| Giske, CG | 1 |
| Samuelsen, Ø | 1 |
| Wretlind, B | 1 |
| Kalin, M | 1 |
| Olsson-Liljequist, B | 1 |
| Zhao, H | 1 |
| Kang, XL | 1 |
| Chen, XL | 1 |
| Wang, JX | 1 |
| Le, Y | 1 |
| Shen, ZG | 1 |
| Chen, JF | 1 |
| Ayoub, T | 1 |
| Arshad, I | 1 |
| Donnellan, I | 1 |
| Cullen, IM | 1 |
| Manecksha, RP | 1 |
| McCullagh, E | 1 |
| Ahmad, S | 1 |
| O'Kelly, F | 1 |
| Flynn, R | 1 |
| McDermott, TE | 1 |
| Murphy, P | 1 |
| Grainger, R | 1 |
| Fennell, JP | 1 |
| Thornhill, JA | 1 |
| Tam, VK | 1 |
| Kung, WH | 1 |
| Li, R | 1 |
| Chan, KW | 1 |
| Bayrak, O | 1 |
| Cimentepe, E | 1 |
| Inegöl, I | 1 |
| Atmaca, AF | 1 |
| Duvan, CI | 1 |
| Koç, A | 1 |
| Turhan, NO | 1 |
| Peltola, V | 1 |
| Svedström, E | 1 |
| Waris, M | 1 |
| Heikkinen, T | 1 |
| Ruuskanen, O | 1 |
| Toyonaga, Y | 1 |
| Kurosu, Y | 1 |
| Kumagai, K | 1 |
| Hori, M | 1 |
| Venuti, M | 1 |
| Orlando, R | 1 |
| Nassuato, G | 1 |
| Martines, D | 1 |
| Lirussi, F | 1 |
| Okolicsanyi, L | 1 |
| George, J | 1 |
| Chakravarthy, S | 1 |
| John, GT | 1 |
| Jacob, CK | 1 |
| Arstila, T | 1 |
| Auvinen, H | 1 |
| Huovinen, P | 1 |
| Kornberg, AE | 1 |
| Sherin, K | 1 |
| Veiga, P | 1 |
| Mydlow, PK | 1 |
| Collins, JJ | 1 |
| Feld, LG | 1 |
| Hasan, S | 1 |
| Hall, FC | 1 |
| Maidment, G | 1 |
| Hvidberg, H | 1 |
| Struve, C | 1 |
| Krogfelt, KA | 1 |
| Christensen, N | 1 |
| Rasmussen, SN | 1 |
| Orrett, FA | 1 |
| Shurland, SM | 1 |
| Cronberg, S | 1 |
| Banke, S | 1 |
| Bergman, B | 1 |
| Boman, H | 1 |
| Eilard, T | 1 |
| Elbel, E | 1 |
| Hugo-Persson, M | 1 |
| Johansson, E | 1 |
| Kuylenstierna, N | 1 |
| Lanbeck, P | 1 |
| Lindblom, A | 1 |
| Paulsen, O | 1 |
| Schönbeck, C | 1 |
| Walder, M | 1 |
| Wieslander, P | 1 |
| Nicolás Torralba, JA | 1 |
| Bañón Pérez, V | 1 |
| Valdelvira Nadal, P | 1 |
| López Cubillana, P | 1 |
| Server Pastor, G | 1 |
| Pérez Albacete, M | 1 |
| Cooper, J | 1 |
| Raeburn, A | 1 |
| Brumfitt, W | 1 |
| Hamilton-Miller, JM | 1 |
| Slack, RC | 1 |
| Mattie, H | 1 |
| van Dokkum, AM | 1 |
| Brus-Weijer, L | 1 |
| Krul, AM | 1 |
| van Strijen, E | 1 |
| Beale, AS | 2 |
| Gisby, J | 2 |
| Sutherland, R | 1 |
| Wijma, J | 1 |
| Kauer, FM | 1 |
| van Saene, HK | 1 |
| van de Wiel, HB | 1 |
| Janssens, J | 1 |
| Uri, JV | 1 |
| Phillips, L | 1 |
| Pitkin, DH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Tolerance and Efficacy of Amiklin Administration During Nosocomial Infections Complicating COVID-19 in the ICU[NCT05511129] | 1,053 participants (Actual) | Observational | 2022-05-12 | Active, not recruiting | |||
| Epidemiology of ST131 in Besançon University Hospital[NCT02853708] | 300 participants (Actual) | Observational | 2015-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for cefuroxime and Escherichia coli Infections
| Article | Year |
|---|---|
Renal parenchymal malacoplakia: a rare cause of ARF with a review of recent literature.
Topics: Acute Kidney Injury; Aged; Biopsy, Needle; Cefuroxime; Diagnosis, Differential; Drug Therapy, Combin | 2003 |
Bilateral emphysematous pyelonephritis responding to nonsurgical management.
Topics: Cefuroxime; Ciprofloxacin; Diabetic Nephropathies; Drug Therapy, Combination; Emphysema; Escherichia | 1995 |
6 trials available for cefuroxime and Escherichia coli Infections
| Article | Year |
|---|---|
Is single-dose fosfomycin trometamol a good alternative for asymptomatic bacteriuria in the second trimesterof pregnancy?
Topics: Adult; Age Factors; Anti-Bacterial Agents; Bacteriuria; Cefuroxime; Drug Administration Schedule; Es | 2007 |
Two-day therapy with cefuroxime axetil is effective for urinary tract infections in children.
Topics: Administration, Oral; Cefuroxime; Child; Child, Preschool; Colony Count, Microbial; Drug Administrat | 1994 |
Fewer bacterial relapses after oral treatment with norfloxacin than with ceftibuten in acute pyelonephritis initially treated with intravenous cefuroxime.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ceftibut | 2001 |
Comparative efficacy and tolerability of cephradine and cefuroxime axetil in the treatment of acute dysuria and/or frequency in general practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacteriuria; Cefuroxime; Cephradine; Escherichia coli In | 1992 |
Definition of urinary tract infection and assessment of efficacy in drug trials--a laboratory perspective.
Topics: Bacteriuria; Cefuroxime; Colony Count, Microbial; Escherichia coli Infections; Female; Humans; Mass | 1992 |
Antibiotics and suction drainage as prophylaxis in vaginal and abdominal hysterectomy.
Topics: Abscess; Bacteroides Infections; Cefuroxime; Cephalosporins; Cystitis; Escherichia coli Infections; | 1987 |
32 other studies available for cefuroxime and Escherichia coli Infections
| Article | Year |
|---|---|
Cefuroxime pharmacokinetics and pharmacodynamics for intravenous dosage regimens with 750 mg or 1500 mg doses in healthy young volunteers.
Topics: Adult; Anti-Bacterial Agents; Cefuroxime; Escherichia coli; Escherichia coli Infections; Female; Hea | 2020 |
Prevalence of O25b-ST131 clone and fosfomycin resistance in urinary Escherichia coli isolates and their relation to CTX-M determinant.
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactamases; Ceftriaxone; Cefuroxime; Ciprofloxacin; DNA, Bacte | 2020 |
Mode of bacterial killing affects the inflammatory response and associated organ dysfunctions in a porcine E. coli intensive care sepsis model.
Topics: Animals; Cefuroxime; Disease Models, Animal; Endotoxins; Escherichia coli; Escherichia coli Infectio | 2020 |
A Cohort Study of Risk Factors That Influence Empirical Treatment of Patients with Acute Pyelonephritis.
Topics: Acute Disease; Adult; Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Ce | 2017 |
Dynamics of Endotoxin, Inflammatory Variables, and Organ Dysfunction After Treatment With Antibiotics in an Escherichia coli Porcine Intensive Care Sepsis Model.
Topics: Animals; Anti-Bacterial Agents; Cefuroxime; Disease Models, Animal; Drug Therapy, Combination; Endot | 2018 |
The Escherichia coli phylogenetic group B2 with integrons prevails in childhood recurrent urinary tract infections.
Topics: Anti-Bacterial Agents; Bacterial Typing Techniques; Cefotaxime; Cefuroxime; Child; Child, Preschool; | 2014 |
Beneficial antimicrobial effect of the addition of an aminoglycoside to a β-lactam antibiotic in an E. coli porcine intensive care severe sepsis model.
Topics: Animals; Anti-Bacterial Agents; Bacteremia; Bacterial Load; Cefuroxime; Critical Care; Disease Model | 2014 |
An in vitro deletion in ribE encoding lumazine synthase contributes to nitrofurantoin resistance in Escherichia coli.
Topics: Aerobiosis; Anaerobiosis; Anti-Bacterial Agents; Base Sequence; Cefuroxime; Drug Resistance, Bacteri | 2014 |
Emerging Escherichia coli O25b/ST131 clone predicts treatment failure in urinary tract infections.
Topics: Aged; Anti-Bacterial Agents; Bacterial Typing Techniques; Cefuroxime; Ciprofloxacin; Cohort Studies; | 2015 |
[The comparison of antibiotic susceptibilities of uropathogenic Escherichia coli isolates in transition from CLSI to EUCAST].
Topics: Amikacin; Ampicillin; Anti-Bacterial Agents; Bacteriuria; Cefuroxime; Ciprofloxacin; Disk Diffusion | 2015 |
Use of cefuroxime for women with community-onset acute pyelonephritis caused by cefuroxime-susceptible or -resistant Escherichia coli.
Topics: Administration, Intravenous; Aged; Anti-Bacterial Agents; Cefuroxime; Community-Acquired Infections; | 2016 |
[Emphysematous cystitis].
Topics: Aged; Breast Neoplasms; Cefuroxime; Cystitis; Diabetes Complications; Diabetes Mellitus, Type 2; Dis | 2016 |
Risk factors and microbiology of wound infections following cesarean delivery: Experience of a single institution.
Topics: Abdomen; Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Cefazolin; Cefuroxime; Cesarean Secti | 2016 |
Xanthogranulomatous pyelonephritis infiltrating the liver.
Topics: Anti-Bacterial Agents; Cefuroxime; Cephalexin; Child; Clindamycin; Combined Modality Therapy; Divert | 2008 |
Estimation of cefuroxime dosage using pharmacodynamic targets, MIC distributions, and minimization of a risk function.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cefuroxime; Creatinine; Drug Admi | 2008 |
[Prophylaxis of postoperative endophthalmitis with intracameral cefuroxime: a five years' experience].
Topics: Anterior Chamber; Anti-Bacterial Agents; Antibiotic Prophylaxis; Cefuroxime; Corynebacterium Infecti | 2009 |
Interplay of efflux, impermeability, and AmpC activity contributes to cefuroxime resistance in clinical, non-ESBL-producing isolates of Escherichia coli.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Boronic Acids | 2009 |
Antibacterial activities of amorphous cefuroxime axetil ultrafine particles prepared by high gravity antisolvent precipitation (HGAP).
Topics: Animals; Anti-Bacterial Agents; Cefuroxime; Chemical Precipitation; Drug Compounding; Escherichia co | 2009 |
Concurrent emphysematous cholecystitis and emphysematous cystitis in a non-diabetic patient.
Topics: Aged, 80 and over; Anti-Infective Agents; Cefuroxime; Cystitis; Drug Therapy, Combination; Emphysema | 2009 |
An 11-year analysis of the prevalent uropathogens and the changing pattern of Escherichia coli antibiotic resistance in 38,530 community urinary tract infections, Dublin 1999-2009.
Topics: Adolescent; Adult; Amoxicillin-Potassium Clavulanate Combination; Ampicillin; Anti-Bacterial Agents; | 2013 |
Pulmonary abscess of viral-bacterial etiology in a neonate.
Topics: Anti-Infective Agents; Cefuroxime; Cephalexin; Escherichia coli Infections; Female; Humans; Infant, | 2007 |
[Fundamental and clinical studies of cefuroxime in pediatric purulent meningitis (author's transl)].
Topics: Cefuroxime; Cephalosporins; Child, Preschool; Drug Evaluation; Escherichia coli Infections; Female; | 1980 |
[Therapeutic effectiveness of metossimine associated with an aminoglycoside in a case of severe gram-negative sepsis].
Topics: Cefuroxime; Cephalosporins; Diabetes Complications; Drug Therapy, Combination; Escherichia coli Infe | 1981 |
Beta-lactam resistance among Escherichia coli and Klebsiella species blood culture isolates in Finnish hospitals. Finnish Study Group for Antimicrobial Resistance.
Topics: Bacteremia; beta-Lactam Resistance; Cefuroxime; Cephalosporins; Drug Utilization; Escherichia coli; | 1994 |
The Dambusters: a case of cerebrospinal and urinary obstruction.
Topics: Aged; Catheterization; Cefuroxime; Ciprofloxacin; Escherichia coli Infections; Humans; Hydrocephalus | 1993 |
Development of a long-term ascending urinary tract infection mouse model for antibiotic treatment studies.
Topics: Animals; Anti-Bacterial Agents; Cefuroxime; Disease Models, Animal; Dose-Response Relationship, Drug | 2000 |
Prevalence of resistance to antimicrobials of Escherichia coli isolates from clinical sources at a private hospital in Trinidad.
Topics: Amoxicillin-Potassium Clavulanate Combination; Ampicillin; Anti-Bacterial Agents; Cefuroxime; Cephal | 2001 |
[Abscess of seminal vesicle: conservative treatment].
Topics: Abscess; Cefuroxime; Cephalosporins; Escherichia coli Infections; Genital Diseases, Male; Humans; Ma | 2001 |
Antibacterial activity of four cephalosporins in an experimental infection in relation to in vitro effect and pharmacokinetics.
Topics: Agranulocytosis; Animals; Cefamandole; Ceftazidime; Ceftriaxone; Cefuroxime; Cephalosporins; Disease | 1990 |
Inactivation of cefuroxime and cefotaxime by Bacteroides fragilis in vitro, and its influence on the treatment of an experimental Escherichia coli/Bacteroides fragilis mixed infection.
Topics: Amoxicillin; Animals; Bacteroides fragilis; Bacteroides Infections; beta-Lactamases; Cefotaxime; Cef | 1989 |
Efficacy of amoxycillin/clavulanic acid in experimental Bacteroides fragilis/Escherichia coli mixed infections.
Topics: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Ampicillin; Animals; Anti-Bacterial Agen | 1988 |
Comparative laboratory studies on alpha-methoxyimino furyl- and phenylacetamido cephalosporins: structure-activity relationships.
Topics: Animals; Bacteria; Cefazolin; Cefuroxime; Cephalosporins; Escherichia coli Infections; Half-Life; Ki | 1986 |